Good afternoon, and welcome to the Spero Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in listen-only-mode. Following the company's ...

Spero Therapeutics Inc reported its financial results for the fourth quarter of 2024, revealing a diluted net loss per share of $0.38, which was slightly below the forecast of $0.36. The company’s ...

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $0.96 per share a year ago.

CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for ...

The film by Akron native Pat Donovan looks at Spero's long career in Rock and Roll, starting with his days as a child working with his father, who was the producer of the syndicated music show ...